ORPHA:98293
Hodgkin lymphoma
- Type
- Clinical group
- Group
- Group of disorders
- Inheritance
- Multigenic/multifactorial
- Age of onset
- Adolescent, Adult, Childhood, Elderly, Infancy
- Status
- active
Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.
1
Names in Orphadata languages
12 of 12 languages| Lang | Name | Synonyms |
|---|---|---|
| en | Hodgkin lymphoma | |
| fr | Lymphome de Hodgkin | Maladie de Hodgkin |
| de | Hodgkin-Lymphom | Hodgkin-Krankheit |
| es | Linfoma de Hodgkin | Enfermedad de Hodgkin |
| it | Linfoma di Hodgkin | Malattia di Hodgkin |
| nl | Hodgkin-lymfoom | Lymfoom van Hodgkin · Ziekte van Hodgkin |
| pt | Linfoma de Hodgkin | |
| pl | Chłoniak Hodgkina | Chłoniak Hodgkina · Choroba Hodgkina |
| cs | Hodgkinův lymfom | Hodgkinova nemoc |
| uk | Лімфома Ходжкіна | |
| zh | 霍奇金淋巴瘤 | |
| tr | Hodgkin lenfoma |
Definition in:
2
Cross-references
qualifier = Orphanet mapping relation| Source | Code | Qualifier | ICD relation | Validation |
|---|---|---|---|---|
| ICD-11 | 2B30 | E | specific | validated |
| MONDO | 0004952 | E | validated | |
| MONDO | 4952 | E | validated | |
| MeSH | D006689 | E | validated | |
| UMLS | C0019829 | E | validated | |
| GARD | 2714 | E | validated | |
| MedDRA | 10020206 | E | validated |
E exact · NTBT this ORPHAcode is narrower than the target · BTNT broader than the target · ND not decided.
3
Classification
Preferential parent (Orphanet linearisation):
Parents in the classifications (2):
- ORPHA:289644Epstein-Barr virus-associated malignant lymphoproliferative disorder
rare neoplastic diseases - ORPHA:223735Lymphoma
rare hematological diseases; rare neoplastic diseases; rare transplant-related disorders
4
Genes
0 directOrphanet records no gene directly on this code.
5
Prevalence and incidence
5 records| Type | Class | Value | Area | Qualification | Validation | Source |
|---|---|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 2.4 / 100 000 | Europe | Value and class | Validated | RARECARE surveillance of rare cancers in Europe[OTHER] |
| Lifetime Prevalence | 1-5 / 10 000 | 46.9 / 100 000 | Europe | Value and class | Validated | 22033323[PMID]_RARECARE surveillance of rare cancers in Europe[OTHER] |
| Annual incidence | 1-9 / 100 000 | 2.8 / 100 000 | United States | Value and class | Validated | National Cancer OTHERitute 2008[OTHER]_22835602[PMID] |
| Annual incidence | 1-9 / 1 000 000 | 0.25 / 100 000 | Japan | Value and class | Not yet validated | emedicine[OTHER] |
| Annual incidence | 1-9 / 1 000 000 | 0.25 / 100 000 | China | Value and class | Not yet validated | emedicine[OTHER] |
Value is Orphadata's ValMoy: the mean estimate per 100 000 for prevalence and incidence, the number of cases or families for case reports.
6
HPO phenotypes
Orphanet has no HPO annotation for this code in this release.
7
Sources for this card
- Orphanet page: orpha.net/en/disease/detail/98293
- This record as JSON: /data/d/98293.json